We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Shenzhen YHLO Biotech Co., Ltd.

  Gold Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufactur... read more Featured Products: More products

Download Mobile App

YHLO Launches New SARS-CoV-2 Neutralization Antibody (NAb) Assay

By LabMedica International staff writers
Posted on 03 Mar 2021
Print article
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has launched its new SARS-CoV-2 NAb test kit designed to detect all antibodies that are able to inhibit the binding between S1 RBD and ACE2 in both CLIA and FIA platforms.

The test is intended to be used for the evaluation of neutralization antibodies in discharged patients, monitor neutralization antibodies in people who had COVID-19 vaccination, and the efficacy of immunotherapy. Neutralization antibody assay is essential for many vaccines and treatments for other infectious diseases, e.g. Anti-HBs assay is measuring neutralization antibody of Hepatitis B Virus. By definition, neutralization antibodies against SARS-CoV-2 can stop COVID-19 Receptor Binding Domain (RBD) from binding to Angiotensin-Converting Enzyme 2 (ACE2) receptor in human cells, which prevent SARS-CoV-2 to invade human cells.

When compared to traditional PRNT and ELISA test, YHLO’s SARS-CoV-2 NAb test kit offers the distinct advantage of being a quantitative test on the CLIA/FIA platform, which provides valuable clinical data to any studies that intend to assess either immune response or therapy efficacy in COVID-19. Additionally, the use of the CLIA/FIA method drastically improves testing capacity and efficiency, aiding the large-scale study on NAb.

Some additional advantages offered by YHLO’s SARS-CoV-2 NAb test kit include quantitative test yielding data with medical value, high throughput with short TAT (first result <30 minutes), full automation which minimizes human-induced error, cost-effectiveness and lower labor intensity, and a dynamic design that mimics the human body internal environment.

Gold Supplier
Silver Supplier
Nucleic Acid Extractor
COVID-19 Anitibody Test
Wastewater SARS-CoV-2 RT-qPCR Kit
SARS-CoV-2 RT-qPCR Kit for Wastewater

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more


view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.